Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.476 DKK 0.68%
Market Cap: 634.2m DKK

Bioporto A/S
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioporto A/S
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Net Change in Cash
kr6.4m
CAGR 3-Years
-43%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Net Change in Cash
-kr5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Net Change in Cash
kr31m
CAGR 3-Years
-43%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Ascendis Pharma A/S
NASDAQ:ASND
Net Change in Cash
€167.4m
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
18%
B
Bavarian Nordic A/S
CSE:BAVA
Net Change in Cash
-kr35.5m
CAGR 3-Years
46%
CAGR 5-Years
32%
CAGR 10-Years
-29%
Saniona AB
STO:SANION
Net Change in Cash
-kr8m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Bioporto A/S
Glance View

Market Cap
634.2m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.27 DKK
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Net Change in Cash?
Net Change in Cash
6.4m DKK

Based on the financial report for Sep 30, 2024, Bioporto A/S's Net Change in Cash amounts to 6.4m DKK.

What is Bioporto A/S's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-21%

The average annual Net Change in Cash growth rates for Bioporto A/S have been -43% over the past three years , -21% over the past five years .

Back to Top